Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05235737
Title The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab (PIRG)
Acronym PIRG
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Medical University of Silesia
Indications
Therapies
Age Groups: adult | senior
Covered Countries POL


No variant requirements are available.